Shigeyuki Itamura

Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic.

Intranasal inoculation of a recombinant influenza virus containing exogenous nucleotides in the NS segment induces mucosal immune response against the exogenous gene product in mice.

[SARS, pandemic influenza, avian influenza: quest for missing link].

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation.

Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies.

Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein.

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.

Pathological and virological analyses of severe acute respiratory syndrome-associated coronavirus infections in experimental animals.

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes.

Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer.

[Trends and perspectives in development of influenza vaccines].

[The latest trend and prospects of development of influenza vaccine].

Newly established monoclonal antibodies for immunological detection of H5N1 influenza virus.

Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis.

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013.

Broad cross-reactive epitopes of the H5N1 influenza virus identified by murine antibodies against the A/Vietnam/1194/2004 hemagglutinin.

Development of a sensitive novel diagnostic kit for the highly pathogenic avian influenza A (H5N1) virus.

Deciphering antigen-responding antibody repertoires by using next-generation sequencing and confirming them through antibody-gene synthesis.

Distorted antibody repertoire developed in the absence of pre-B cell receptor formation.

Efficient protection of mice from influenza A/H1N1pdm09 virus challenge infection via high avidity serum antibodies induced by booster immunizations with inactivated whole virus vaccine.